Varex Imaging Reports Strong Q1 2026 Earnings with Growth in Industrial Segment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 11 2026
0mins
Should l Buy VREX?
Source: seekingalpha
- Revenue Growth: Varex Imaging reported Q1 2026 revenue of $210 million, a 5% year-over-year increase, driven by strong cargo systems performance and a 17% rise in the Industrial segment, nearing the high end of guidance.
- Stable Medical Segment: The Medical segment contributed $145 million, accounting for 69% of total revenue, with continued strength in CT equipment and increased customer engagement around next-generation system designs, boosting market confidence despite past challenges.
- Optimistic Outlook: Management provided Q2 2026 revenue guidance of $210 million to $225 million, with non-GAAP EPS expected between $0.15 and $0.25, reflecting confidence in future demand, particularly in the Industrial sector.
- Inventory Management Challenges: Despite a net income of $2 million in Q1, inventory rose by $29 million to $328 million, prompting management to plan a reduction of $10 to $15 million in inventory over the next quarters to address potential market volatility.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VREX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VREX
Wall Street analysts forecast VREX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 11.830
Low
16.00
Averages
17.00
High
18.00
Current: 11.830
Low
16.00
Averages
17.00
High
18.00
About VREX
Varex Imaging Corporation is a designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems. The Company’s segments include Medical and Industrial. Its Medical segment designs, manufactures, sells and services X-ray imaging components, including X-ray tubes, flat panel and photon-counting detectors and accessories, high-voltage connectors, image-processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, and coolers. Its Industrial segment designs, develops, manufactures, sells, and services X-ray imaging products for use in a number of applications, including security applications for cargo screening at ports and borders, baggage screening at airports, and nondestructive testing, irradiation, and inspection applications used in a number of other verticals.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Stable Revenue Performance: Varex Imaging reported Q2 revenue of $216 million, aligning with guidance, with a 2% increase in medical revenue driven by strong CT sales, indicating stability in both medical and industrial sectors despite some softness in industrial performance.
- Strong Gross Margin: The non-GAAP gross margin stood at 34%, at the high end of guidance, with non-GAAP EPS of $0.21, reflecting effective cost control amidst rising raw material prices, showcasing the company's resilience in maintaining profitability.
- Successful Debt Restructuring: The company completed debt refinancing, resulting in reduced outstanding debt and lower annual interest expenses, enhancing its capital structure and providing greater flexibility for future investments and growth initiatives.
- Optimistic Future Outlook: Full fiscal year 2026 revenue is expected to range between $860 million and $880 million, with Q3 revenue guidance set between $210 million and $225 million, demonstrating the company's confidence in future growth despite facing some cost and logistics challenges.
See More
Q2 Adjusted EPS: VAREX Imaging reported an adjusted earnings per share (EPS) of USD 0.21 for the second quarter.
Comparison with Estimates: This EPS figure matches the estimates provided by IBES, which also projected an EPS of USD 0.21.
See More
- Earnings Release Schedule: Varex Imaging Corporation will announce its unaudited financial results for Q2 of fiscal year 2026 after market close on May 7, 2026, which is expected to significantly impact investor sentiment.
- Conference Call Details: Following the earnings release, Varex will host a conference call at 3:00 PM Mountain Time, allowing investors to participate via 877-524-8416 (U.S.) or 412-902-1028 (non-U.S.), enhancing investor engagement and communication.
- Webcast and Replay Availability: The conference call will be webcast live and accessible on the company's website, with a replay available from May 7 to May 21, ensuring broad dissemination of information and transparency for stakeholders.
- Company Background: Varex Imaging Corporation is a leading manufacturer of X-ray imaging components with over 70 years of innovation, whose products are utilized in medical, industrial, and security imaging applications, underscoring its significant market presence.
See More
- Credit Agreement Overview: Varex Imaging has entered into a $490 million Credit and Guaranty Agreement on March 13, 2026, which includes a $350 million secured term loan and a $100 million secured revolving credit facility, maturing in 2031, thereby enhancing the company's financial flexibility.
- Debt Redemption Plan: The company plans to redeem $368 million of its 7.875% Senior Secured Notes on March 16, 2026, using funds from the new credit agreement, which is expected to reduce annual cash interest expenses by over $7 million, significantly improving its financial position.
- Interest Rate Management Strategy: Varex has entered into an interest rate swap that effectively fixes the variable SOFR rate at 3.65%, with an applicable margin set at 2.50%, which will help lower financing costs and enhance future free cash flow generation capabilities.
- Strategic Investment Direction: The CFO stated that this financing will support continued investment in the core business while prioritizing long-term shareholder value, demonstrating the company's confidence and commitment to future growth.
See More
- Investor Conference Schedule: Varex Imaging announced its participation in Oppenheimer's 36th Annual Healthcare, MedTech & Services Virtual Conference on March 17, 2025, at 10:40 AM ET, and the Sidoti Small Cap Virtual Conference on March 18, 2026, at 1:00 PM ET, showcasing the company's innovations and market outlook in medical imaging.
- Webcast Access: Investors can access the conferences via the company's website or provided webcast links, ensuring transparent communication with investors and enhancing market confidence.
- Company Background: Varex Imaging is a leading innovator in X-ray imaging components with over 70 years of successful innovation history, with products widely used in medical, industrial, and security imaging, demonstrating the company's deep technological expertise.
- Global Workforce Distribution: Varex employs approximately 2,400 people across North America, Europe, and Asia, showcasing its global operational capabilities and market reach, further solidifying its leadership position in the imaging industry.
See More









